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AbstrAct 
Background: Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a 
therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the stand-
ard protocol, which associates maximally tolerated dose of lipid-lowering medications with lipoprotein apheresis (LA). 
Lomitapide is an emerging therapy in HoFH, but its place in the treatment algorithm is disputed because a compari-
son of its long-term efficacy versus LA in reducing LDL-C burden is not available. We assessed changes in long-term 
LDL-C burden and goals achievement in two independent HoFH patients’ cohorts, one treated with lomitapide in Italy 
(n = 30) and the other with LA in France (n = 29).
Results: The two cohorts differed significantly for genotype (p = 0.004), baseline lipid profile (p < 0.001), age of treat-
ment initiation (p < 0.001), occurrence of cardiovascular disease (p = 0.003) as well as follow-up duration (p < 0.001). 
The adjunct of lomitapide to conventional lipid-lowering therapies determined an additional 58.0% reduction of 
last visit LDL-C levels, compared to 37.1% when LA was added (padj = 0.004).Yearly on-treatment LDL-C < 70 mg/
dl and < 55 mg/dl goals were only achieved in 45.5% and 13.5% of HoFH patients treated with lomitapide. The 
long-term exposure to LDL-C burden was found to be higher in LA than in Lomitapide cohort (13,236.1 ± 5492.1 
vs. 11,656.6 ± 4730.9 mg/dL-year respectively, padj = 0.002). A trend towards fewer total cardiovascular events was 
observed in the Lomitapide than in the LA cohort.
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Background
Homozygous familial hypercholesterolemia (HoFH) is 
a rare inherited disorder of lipid metabolism charac-
terized by marked elevation of low-density lipoprotein 
cholesterol (LDL-C) caused by an almost abolished 
function of LDL receptor (LDLR) [1]. Typically, HoFH 
patients develop clinical complications of atheroscle-
rotic cardiovascular disease (ASCVD) early in life [2–5] 
due to the very high life-long LDL-C burden associated 
with this condition [6, 7]. Therefore, an early, intensive 
LDL-C lowering therapy is mandatory to control the 
high risk of ASCVD in HoFH.
Lipoprotein apheresis (LA) in addition to statins 
and ezetimibe is considered the standard of therapy 
in HoFH [1, 8]. LA transiently removes LDL particles 
from plasma during extracorporeal circulation by selec-
tively binding apolipoprotein B (ApoB)-containing lipo-
proteins and has been demonstrated to be very effective 
in lowering LDL-C levels [8, 9]. However, an optimal 
inter-procedures LDL-C control is difficult to reach 
due to the post-treatment LDL-C rebound and, there-
fore, the residual cardiovascular risk of these patients 
remains high [10].
In recent years, promising new drugs in the treatment 
of HoFH have become available [11]. Monoclonal anti-
bodies inhibiting proprotein convertase subtilisin/kexin 
type 9 (PCSK9i) have been reported to decrease LDL-C 
by an additional 24% when added to background lipid-
lowering therapies in HoFH [11]. However, PCSK9i are 
mostly effective in patients with residual LDLR function, 
showing very limited effect in those carrying null muta-
tion or homozygous mutation in the LDLRAP1 gene [12].
Lomitapide, an inhibitor of microsomal triglycerides 
transferase protein (MTP), has been proven to decrease 
by almost 50% LDL-C levels in HoFH in adjunct to 
other lipid-lowering medications (including LA) [13]. 
Recent real-world studies have confirmed the efficacy 
and safety of lomitapide in the treatment of adults and 
children with HoFH [11–14]. As lomitapide acts by 
decreasing liver secretion of VLDL and, consequently, 
VLDL-derived LDL production [15], its efficacy appears 
to be independent from the severity of functional 
impairment of LDLR pathway [16]. Some real-word 
studies have reported that the addition of lomitapide to 
background therapies results in the discontinuation of 
LA in many patients with HoFH [14].
The advent of novel therapeutic options is rapidly 
changing the therapeutic armamentarium for the man-
agement HoFH. Therefore, some efforts must be done to 
compare the effectiveness of emerging versus standard 
therapies in controlling LDL-C burden in these patients. 
Considering the rarity of the disease and the fact that 
large and formal randomized clinical trials aimed at com-
paring lomitapide versus LA are not feasible, we believe 
that a real-world survey might help in clarifying the ben-
efit of these two treatments. However, a comparison of 
benefit of lomitapide versus LA in the long-term control 
of LDL-C burden in HoFH is not available to date.
Our aim was to indirectly compare the long-term LDL-
lowering effectiveness of these two treatments through-
out the evaluation of two independent HoFH cohorts 
treated with lomitapide or LA. We therefore assessed 
LDL-C reduction, target achievement and long-term 
LDL-C burden in these two populations. As an explora-
tory analysis, we also aimed at evaluating major athero-
sclerotic cardiovascular events (MACE) incidence during 
follow-up in the two cohorts.
Results
The two cohorts differed significant for demographic, 
clinical, genetic, and biochemical characteristics as 
shown in Table 1. The list of causative HoFH mutations is 
reported in the Additional file 1: Table 1.
Patients from the LA cohort showed a more severe gen-
otype as compared to the Lomitapide cohort (p = 0.004). 
The age of initiation of treatment with LA was ear-
lier than that of lomitapide (p < 0.001). First ASCVD 
occurred earlier in the LA cohort (p = 0.003), while the 
overall prevalence of ASCVD did not differ between the 
two cohorts.
Patients in the Lomitapide cohort exhibited lower val-
ues of untreated (p < 0.001), lowest on conventional lipid-
lowering treatment (LLT) (p = 0.01) or baseline (p < 0.001) 
LDL-C as compared with those in the LA cohort.
Lipid changes during follow‑up
The median follow-up duration was 16.7 years in the LA 
cohort and 2.3  years in Lomitapide cohort (p < 0.001) 
(Table 2).
Figure  1 shows changes in TC and LDL-C concen-
trations in the two cohorts before and after addition of 
lomitapide or LA. The addition of lomitapide to standard 
Conclusions: In comparison with LA, lomitapide appears to provide a better control of LDL-C in HoFH. Further stud-
ies are needed to confirm this data and establish whether this translates into a reduction of cardiovascular risk.
Keywords: Homozygous hypercholesterolemia, Lipoprotein apheresis, Lomitapide, LDL, Therapeutics, Genetic 
disease, Cholesterol burden
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Table 1 Baseline clinical characteristics of HoFH patients
Data are represented median (interquartile range) and number (percentage) as appropriate. Pre-treatment LDL-C burden was calculated as: 
(
LDL− Cbaseline ∗ AgefirstLAorLomitapideprescrption
)
ARH, Autosomal Recessive Homozygous; T2DM, type 2 diabetes; HTN, hypertension; LLT, Lipid Lowering Therapy; LDL-C, low density lipoprotein cholesterol; TC, total 
cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglycerides; BMI, body mass index; HTN, hypertension; T2DM, type 2 diabetes; LA, Liporprotein apheresis; 
PCKS9i, Proprotein convertase subtilisin/kexin type 9 inhibitors; MACE, Major Atherosclerotic Cardiovascular Events; CHD, coronary heart disease; PAD, peripheral 
artery disease; NS, not significant
a 1 patient from Africa, 9 from North-Africa, 1 from central-eastern Europe, 1 from Antille, 3 from South Asia and 3 from Turkey (for one patient the information on 
ethnicity was not available)
b The genotype was defined as uncertain if molecular diagnosis was not available or the molecular testing indicated the presence of variants of uncertain significance 
(VUS)
c Untreated LDL-C values were available for 21 and 12 subjects in the Lomitapide and LA cohort, respectively
d LA was started at this visit
Lomitapide cohort (N = 30) LA cohort (N = 29) p
Geographic origin
 European Non-Finnish-Southern European, n (%) 29 (96.7) 10 (34.5)  < 0.001
 Others, n (%)a 1 (3.3) 19 (65.5)
Demographic
 Age, years 40.0 (27.5–56.5) 18.0 (10.5–30.5)  < 0.001
 Male, n (%) 15 (50.0) 14.0 (48.3) NS
Genotype
  Uncertainb 12 (40.0) 13 (44.8) 0.004
 ARH 6 (20.0) 2 (6.9)
 Defective/defective 9 (30.0) 1 (3.4)
 Null/defective 1 (3.3) 1 (3.4)
 Null/null 2 (6.7) 12 (41.4)
 Xanthomata, n (%) 26 (86.7) 27 (93.1) NS
Risk factors, n (%)
 Smoking 4 (13.3) 2 (6.9) NS
 T2DM 1 (3.3) 0 NS
 HTN 11 (36.7) 0  < 0.001
Plasma lipids (mg/dl)
 Untreated LDL-Cc 481.4 ± 153.1 794.3 ± 344.2 0.01
 Lowest LDL-C on conventional LLT before LA/Lomitapide 246.5 (170.3–295.8) 502.0 (309.5–606.0)  < 0.001
 Pre-treatment LDL-C burden (mg/dL-year) 11,463.9 (6751.5–14,468.9) 7313.5 (4302.1–11,451.3) 0.034
 Baseline TC 357.6 ± 136.5 510.1 ± 183.6 0.001
 Baseline HDL-C 44.7 ± 12.9 30.3 ± 9.5  < 0.001
 Baseline LDL-C 272.5 ± 108.8 453.0 ± 179.5  < 0.001
 Baseline TG 96.5 (66.8–132.0) 82.5 (59.8–144.0) NS
LLT, n (%)
 None 1 (3.3) 0 NS
 LA 8 (26.7) 0d 0.003
 PCKS9i 6 (20.0) 0 0.011
 Statin 29 (96.7) 28 (96.6) NS
 Ezetimibe 27 (90.0) 11 (37.9)  < 0.001
 Fibrate 1 (3.3) 2 (6.9) NS
 Porto-caval shunt 0 2 (6.9) NS
 Resins 0 9 (31.0) 0.001
Major atherosclerotic cardiovascular events (MACE)
 Age at first MACE 35.0 (30.0–52.5) 19.0 (14.0–35.0) 0.003
 Total MACE, n (%) 17 (56.7) 13 (44.8) NS
CHD 15 (50.0) 9 (31.0)
Stroke 0 1 (3.4)
PAD 1 (3.3) 3 (10.3)
Carotid revascularization 5 (16.7) 2 (6.9)
Aortic valve replacement 4 (14.3) 5 (19.2)
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LLT resulted in a further 58.0% reduction in the last visit 
LDL-C, compared to 37.1% LDL-C reduction after the 
addition of LA (p = 0.013). These results were independ-
ent from genotype, ethnicity, untreated LDL-C levels, 
gender and age at baseline (Lomitapide vs. LA cohort β 
-0.673 padj = 0.004, data not shown).
The yearly variation of LDL-C values in the two cohorts 
is reported in Fig.  2. The mean yearly on-treatment 
LDL-C percent reduction (Panel A) as well as the abso-
lute yearly on-treatment LDL-C levels (Panel B) at 9 years 
were significantly lower in the Lomitapide cohort as com-
pared with the LA cohort and this difference persisted 
after adjusting for genotype, gender, untreated LDL-C, 
Table 2 Follow-up lipid profile, lipid lowering therapies and MACE in HoFH cohorts
Data are represented as median (interquartile range), mean (standard deviation) or number (percentage) as appropriate. For estimation of incident MACE and Incident 
Rate of incident MACE (× 1000 person-years) please refer to Methods. Duration of follow-up has been calculated as the difference between the date of the last and the 
baseline visit with LA or lomitapide. On-treatment LDL-C burden was calculated as: (LDL− Cfollow−up ∗ Yearsfollow−up)
T2DM, type 2 diabetes; HTN, hypertension; LDL-C, low density lipoprotein cholesterol; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; TG, 
triglycerides; LLT, Lipid Lowering Therapy; LA, Lipoprotein apheresis; PCKS9i, Proprotein convertase subtilisin/kexin type 9 inhibitors; MACE, Major Atherosclerotic 
Cardiovascular Events; CHD, coronary heart disease; PAD, peripheral artery disease; IR, incident rate; NS, not significant
Lomitapide cohort (N = 30) LA cohort
(N = 29)
p
Duration of follow-up (years) 2.2 (1.0–3.7) 16.5 (9.0–25.5)  < 0.001
Risk factors, n (%)
 Smoking 2 (6.7) 7 (24.1) 0.006
 T2DM 1 (3.3) 0 NS
 HTN 11 (36.7) 7 (24.1) NS
Plasma lipids (mg/dl)
 On-treatment LDL-C 111.4 (83.7–177.8) 247.2 (217.9–340.8)  < 0.001
 On-treatment LDL-C burden (mg/dL-year) 293.0 (153.0–454.8) 3849.3 (2238.3–7045.5)  < 0.001
 Last visit TC 169.0 (126.2 – 276.7) 390.5 (321.9 – 500.0)  < 0.001
 Last visit HDL-C 47.5 (38.7 – 60.0) 30.6 (19.7 – 40.8) 0.001
 Last visit LDL-C 114.0 (64.7 – 202.95) 340.5 (280.5 – 418.8)  < 0.001
 Last visit TG 58.0 (35.0 – 81.0) 92.7 (65.7 – 152.9) 0.001
LLT at last visit, n (%)
 LA 0 29 (100)  < 0.001
 PCKS9i 5 (16.7) 1 (3.4) NS
 Statin 29 (96.7) 27 (93.1) NS
 Ezetimibe 28 (93.3) 27 (93.1) NS
 Fibrate 0 0 -
 Porto-caval shunt 0 1 (3.4) NS
 Resins 0 0 -
Incident MACE
 Cumulative number of MACE 7 42 -
 Individual MACE event, n (%) 4 (13.3) 16 (55.2) 0.001
CHD 3 (10.0) 11 (37.9) 0.012
Stroke 0 2 (6.9) NS
PAD 0 14 (48.3) 0.001
Carotid revascularization 1 (3.3) 2 (6.9) NS
Aortic Valve replacement 1 (3.3) 6 (22.2) 0.048
Death for cardiovascular disease 1 (3.3) 4 (14.3) NS
Death for other reason 0 1 (3.6) NS
Number of MACE per patient, n (%)
0.003 0 26 (86.7) 13 (44.8)
 1 3 (6.7) 6 (20.7)
 ≥ 2 2 (6.7) 10 (34.5)
IR per 1000 person/years 77.6 86.9 -
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age at baseline and ethnicity (respectively padj < 0.001 for 
both). The percentage of subjects that achieved a yearly 
on-treatment LDL-C percent reduction greater that 
50% from baseline was 77.3% (N = 17) in the Lomitapide 
cohort and 24.1% (N = 7) in the LA cohort (p < 0.001). 
Within the Lomitapide cohort, 45.5% and 13.6% HoFH 
patients reached a yearly on-treatment LDL-C value of 
LDL-C ≤ 70  mg/dl or 55  mg/dl, respectively [Pearson 
chi-squared = 16.4, p = 0.001 vs. LA cohort, Fig. 3 (Panel 
A) and Pearson chi-squared 4.2, p = 0.04 vs. LA cohort, 
Fig. 3 (Panel B)].
Finally, when we estimated the LDL-C burden, HoFH 
patients exposed to lomitapide exhibited a significantly 
lower total LDL-C burden as compared with patients in 
the LA cohort and this persisted after adjustment for 
age at follow-up, untreated LDL-C values, genotype, 
ethnicity, gender (11,656.6 ± 4730.9  mg/dL-year vs. 
13,236.1 ± 5492.1  mg/dL-year, padj = 0.002, Additional 
file  2: Fig.  1, Panel A). Indeed, as compared to values 
before adding lomitapide, LDL-C burden at last visit 
decreased by 97.9% (Additional file  2: Fig.  1, Panel B), 
while after addition of LA this parameter was reduced 
by 52.0% (Additional file  2: Fig.  1, Panel C). These 
results were confirmed after adjustment for untreated 
LDL-C values, genotype, ethnicity, gender (padj = 0.045) 
and were not related to the ongoing background LLT 
(Table 2).
Cardiovascular outcomes
As an exploratory analysis, we compared the occur-
rence of MACE during follow-up in HoFH patients 
receiving lomitapide or LA. In this analysis we included 
Fig. 1 Total and LDL cholesterol changes in HoFH according to lipid-lowering therapies. Box plot graphs represent median values of TC and LDL-Cs. 
Lipid values are shown in 4 different shades of green corresponding to the untreated, lowest on conventional LLT, baseline (before initiation of 
lomitapide or LA treatment) and at last visit measurements. For the definition of untreated, lowest values on conventional LLT, baseline and last 
visit see Material and Methods. In A are reported data observed in the lomitapide cohort whereas in B those in the LA cohort. LDL-C, low density 
lipoprotein cholesterol; LLT, lipid-lowering therapy; LA, lipoprotein apheresis; NS, not significant
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only patients that had been on treatment for at least 
1  year. The absolute number of incident MACE in 
the Lomitapide cohort was lower than that in the LA 
cohort (13.3% vs. 55.2%; p < 0.001). When we estimated 
the MACE IR standardized for time of exposure, the 
IR in the Lomitapide was lower than that in the LA 
cohort (77.6 vs. 86.9 per 1000 person/years) (Table 2). 
Results of the multivariate Cox regression analysis did 
not reveal significant difference in the risk of incident 
MACE (or its recurrence) in Lomitapide as compared 
with LA cohort.
Discussion
Our findings suggest that lomitapide in addition to sta-
tin/ezetimibe treatment might be more efficacious than 
LA in the long-term reduction of LDL-C. Indeed, HoFH 
patients receiving lomitapide presented larger LDL-C 
percent reduction in the last visit as compared to those 
on LA and the proportion of patients reaching a yearly 
on-treatment LDL-C < 70  mg/dl was higher in those 
treated with lomitapide than in those with LA. Same 
results were obtained when we analysed changes in the 
mean percent reduction of LDL-C during time (up to 
9 years) showing that patients in the Lomitapide cohort 
achieved a greater LDL-C percent reduction from base-
line independently from possible confounders. Finally, 
the reduction of cumulative LDL-C burden, which is con-
sidered a strong predictor of risk of vascular damage in 
FH [6, 17], was larger in patient exposed to lomitapide 
than in those exposed to LA.
The LDL-C goals achieved in our LA cohort are con-
sistent with those reported in previous studies where LA 
was used as the sole therapeutic intervention [6, 7, 18]. 
Recently published data from the UK Lipoprotein Apher-
esis Registry including both HeFH (N = 58) and HoFH 
(N = 30) have shown that the overall reduction in LDL-C 
interval means was 43.14% [19]. Furthermore, in a previ-
ous analysis by Bruckert et al. [6], authors found a reduc-
tion in TC by 20% in LA treated patients. On the other 
hand, the LDL-C lowering efficacy of lomitapide was 
almost superimposable to that already described in Phase 
3 trial [13] and real-world study [14].
As an exploratory analysis, we noted that HoFH 
patients who were exposed to lomitapide experienced 
less cardiovascular events than those who had been 
treated with LA and this effect was particularly evident 
for CHD, PAD and aortic valve replacement events. 
Albeit this observation must be taken with great caution 
Fig. 2 Yearly changes of LDL-C in Lomitapide (green) and LA (light blue) cohort during follow-up. As the maximum duration of follow-up in the 
Lomitapide cohort was about 9 years, we compared the two cohorts in the same interval of time. Data are reported as mean values ± 2 standard 
errors per each time-point. A. HoFH subjects treated with lomitapide achieved significantly greater mean yearly LDL-C percent reduction from 
baseline as compared with those on LA. Data are reported as mean percent reduction ± 2 standard errors per each time-point. B. HoFH subjects 
treated with lomitapide achieved significantly lower mean yearly LDL-C values as compared with those on LA.  Padj, value is adjusted for genotype, 
ethnicity, gender, untreated LDL-C and age at baseline. BL, baseline; LDL-C, low density lipoprotein cholesterol; LA, lipoprotein apheresis
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due to the nature of the comparison and the size of 
cohorts, it may suggest a benefit of lomitapide on car-
diovascular risk. One might speculate that this might be 
related, at least to some extent, to the increased efficacy 
of lomitapide in reducing the burden of LDL-C. In fact, 
the role of cholesterol lifelong exposure on cardiovascu-
lar risk in HoFH has been widely explored. Previous data 
from the French HoFH cohort showed that the cumula-
tive total cholesterol exposure was highly associated with 
the incidence of MACE [6]. Accordingly, Thompson et al. 
[7] insisted on the role of on-treatment LDL-C levels as 
the main determinant of overall HoFH survival. Also, 
Raal et al.[18] showed that the cardiovascular protection 
in HoFH was related to the on-treatment LDL-C levels, 
estimating that a LDL-C reduction of about 30% trans-
lated into almost 50% reduction of risk. However, further 
studies are needed to confirm this observation defini-
tively establishing the role of lomitapide in reducing car-
diovascular risk in HoFH.
Fig. 3 Individual yearly on-treatment LDL-C levels in Lomitapide and LA cohort. Individual yearly on-treatment LDL-C has been calculated as the 
average of yearly LDL-C measurements. In A are reported data in the Lomitapide cohort whereas in B those in the LA cohort. LDL-C, low density 
lipoprotein cholesterol; LA, Lipoprotein apheresis
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Safety data in the two cohorts have been described 
in detail elsewhere [14, 20]. The most common adverse 
events (AE) associated with LA included hypotension, 
nausea, abdominal discomfort, tingling, chest pain, vas-
ovagal reaction and prolonged bleeding from anticoagu-
lant. Anemia was another common adverse event easily 
managed by iron supplementation. In addition, patients 
on ACE-inhibitors before the beginning of LA were sys-
tematically withdrawn from the treatment in order to 
prevent anaphylactic-like reactions [21, 22]. Conversely, 
as expected the most common AE in the Lomitapide 
cohort was diarrhea that occurred in 41.2% of cases 
(data not shown). The proportion of patients referring 
gastrointestinal AE, however after 1  year of treatment, 
decreased to 16.6% after 1 year of treatment. One patient 
experienced liver function test elevation (> 5 ULN) after 
3  months of treatment that was managed by holding 
lomitapide and statins and then making rechallenge (data 
not shown).
Some final considerations deserve the cost analysis of 
both LA and lomitapide treatments. Although this issue 
is difficult to be handled since the process of reimburse-
ment is different in France and Italy, the direct costs of 
these therapies appear to be quite comparable between 
the two countries. Considering a weekly LA regimen 
treatment, the expected annual cost of LA would be 
about 90,000 euros while that of lomitapide is 180,000 
euros. This economic evaluation does not take into 
account the social and personal costs of LA, as a result 
of the number of lost working days, not to mention the 
psychological burden. Further studies need to be done to 
better explore the pharmaco-economic aspect of these 
two therapies thus better allowing to compare the cost–
benefit of these two treatments.
Limitations
We acknowledge several weaknesses of the present study: 
the retrospective, cross-sectional observational design, 
and the heterogeneity of the two cohorts.
Patients from the LA cohort exhibited higher 
untreated and baseline LDL-C values: this observa-
tion might be explained by the higher variability in 
geographic origin in these patients, which can result 
in different socio-cultural habits having a different 
impact on the overall lipid profile. Nevertheless, it can 
be the reflection of an overall lower efficacy of baseline 
treatment in relation with a longer follow-up: high-
dose statins were not used in HoFH children until last 
decade (and age at first diagnosis was lower in the LA 
cohort), and ezetimibe was only introduced in 2005. 
Other treatments, as fibrates and cholestyramine, 
which were used in the LA cohort primarily because of 
patients’ age, have a more limited effect on LDL-C than 
high-dose statins plus ezetimibe.
In addition, LDL-C response to treatments might 
have been also influenced both by the higher percent-
age of patients classified as carrying null/null mutations 
and by a more heterogeneous geographic origin within 
the LA cohort. However, it must be noted that in order 
to limit the confounding effect of these factors on the 
results, the efficacy of lomitapide versus LA has been 
evaluated adjusting for both the severity of genotype 
and the geographic origin.
It is important to note that we did not systematically 
collect safety data as this was not the aim of the pre-
sent study that was primarily focused on describing the 
independent efficacy of these two treatments. More 
studies are needed to address this point in order to bet-
ter clarify the cost-benefits of these two treatments.
We also have to acknowledge that due to the retro-
spective nature of the study, we did not retrieve infor-
mation on adherence to concomitant lipid lowering 
therapies thus not allowing us to make any considera-
tion on the possible effect of the adherence to back-
ground lipid lowering therapies on LDL-C control.
Another possible limitation of our results is the dura-
tion of follow-up that was markedly different in the 
two cohorts. This could be easily explained by the fact 
that LA treatment is available from 1990 and is author-
ized for use also in children whereas the availability of 
lomitapide has only been available for less than 10 years 
with no authorization to use in minors.
Finally, it is possible that the differences in follow-up 
duration as well as in baseline characteristics between 
the two cohorts might also have influenced the com-
parison of the effect of these two treatments on ath-
erosclerotic burden making any observation on MACE 
only a conjecture. More studies are needed to clarify 
the benefit of lomitapide on MACE occurrence.
Considering all these limitations, the clinical implica-
tions of our analyses should be considered with much 
caution, especially because these findings are derived 
from an indirect comparison and might be biased by 
several confounding factors.
Conclusion
In summary, we observed in an indirect comparison 
that lomitapide appears to be more effective than LA 
in controlling atherogenic lipoproteins in HoFH. In 
major guidelines, LA in adjunct to statins and ezetimibe 
remains the first-choice therapy in the treatment of 
HoFH [1]. However, our results may open the perspec-
tive in which lomitapide, in addition to statins and 
ezetimibe could be considered as first-line treatment in 
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HoFH. Further studies are necessary in order to formu-
late an updated protocol for the treatment of HoFH that 
integrates old and new treatments in a rationale and cost-
effective algorithm.
Material and methods
Study aim, setting and design
To assess LDL-C reduction, target achievement and 
long-term LDL-C burden in two HoFH cohorts, one 
treated with LA, one with Lomitapide, both on top of 
current available pharmacological treatment. Taking 
advantage of the early availability of lomitapide in Italy 
versus later availability in France, we designed a survey 
in which we retrospectively collected clinical and bio-
chemical information of two independent cohorts of 
patients with HoFH treated with lomitapide in Italy or 
LA in France.
Patients’ selection
HoFH patients known to be receiving lomitapide in Italy 
were considered for this survey. The inclusion crite-
ria were: (1) molecularly or clinically defined HoFH, (2) 
age > 18 years, (3) treatment with lomitapide for at least 
1  month. All identified patients (n = 34) agreed to par-
ticipate. Of these, 8 patients were receiving LA plus lomi-
tapide at baseline visit. Since in these patients LA therapy 
was stopped within 1 year from starting lomitapide and 
the lipid profile did not differ from that of those receiv-
ing lomitapide only, they were kept in the present analy-
sis. Conversely, 4 patients with incomplete lipid profiles 
during follow-up were excluded. Thus, the Lomitapide 
cohort included 30 HoFH patients.
The French cohort consisted of all molecularly con-
firmed HoFH patients referred to the Pitié-Salpêtrière 
University Hospital who had undergone at least one ses-
sion of LA. These patients were part of the French Reg-
istry of Familial Hypercholesterolemia (REFERCHOL). 
Details about this registry have been previously reported 
[28]. A total of 29 French HoFH patients were considered 
for the present analysis (LA cohort).
Data collection
For the Lomitapide cohort, physicians were asked to ret-
rospectively revise medical records and extract demo-
graphic and clinical information. Details of concomitant 
lipid-lowering therapy, dosages of lomitapide and base-
line plasma lipid values as well as those ones at last fol-
low-up visit were also retrieved. No information on side 
effects, adherence to medications or diet was obtained.
For the LA cohort, the same data were extracted by two 
Authors (LD and AG) from REFERCHOL and harmo-
nized for comparison with the Italian database.
Genotypes underlying HoFH in both Italian and French 
cohort were retrieved by medical records and ascertained 
as previously reported [6, 14, 23, 24].
Baseline lipid values were defined as those at the date 
of initiation of lomitapide or LA treatment. Conversely, 
last follow-up data were defined as those at the time of 
the last clinic visit as of December 2019. The duration of 
follow-up was calculated as the difference between last 
and baseline visit.
Finally, data on MACE at baseline and during follow-
up were collected. MACE was defined as a composite of 
angina, acute myocardial infarction, coronary, carotid or 
peripheral revascularization (as well as hemodynamic 
stenosis without revascularization) and ischemic stroke, 
aortic valve replacement and death for cardiovascular 
disease [25]. They were identified by either self-reported 
medical history and/or hospital admission documented 
in the medical record.
Laboratory measurements
In both cohorts, blood samples were collected early in 
the morning after overnight fasting. In HoFH patients 
undergoing LA, pre- and post-treatment samples were 
collected. Aliquots of plasma were used to determine 
total cholesterol (TC), high-density lipoprotein cho-
lesterol (HDL-C) and triglycerides (TG) following 
standard procedures. LDL-C values were calculated by 
using the Friedewald’s formula. No complete informa-
tion was available on ApoB, Lp(a), γGT, CPK and CRP, 
so that these data were not included in the present 
analysis.
The estimation of changes in plasma lipid during 
therapy was carried out using the following reference 
values: (1) untreated values, corresponding to the lipid 
profile at the worst LDL-C measurement available in 
medical charts while the patient was not receiving any 
treatment; (2) lowest lipid profile on conventional ther-
apies, estimated as the lipid profile corresponding to 
the lower LDL-C value with “conventional treatment” 
(as statins ± ezetimibe ± fibrates ± resins ± porto-caval 
shunt ± PCSK9i) before the beginning of lomitapide/
LA; (3) baseline values, corresponding to the time of 
beginning lomitapide or LA; (4) last visit values, corre-
sponding to the last visit when patients were receiving 
lomitapide or LA up to December 2019. It is worth men-
tioning that only two patients had weekly LA whereas 
the remaining were treated on a bi-weekly basis. The 
overall adherence to LA was on average > 80%, as previ-
ously reported [20].
For patients on LA pre- and post-apheresis measure-
ments have been collected to estimate the TC and LDL-C 
interval means according to the following formula: 
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The on-treatment cholesterol ( Cfollow−up ) was rep-
resented by the average of all LDL-C measurements 
obtained during follow-up in the Lomitapide cohort or 
by LDL-C interval means in the LA cohort.
Cholesterol burden estimation
Cholesterol burden was calculated according to the fol-
lowing formula:
where CholesterolBurdenpre− treatment = (Cbaseline∗
∗AgefirstLAorLomitapideprescrption
)
   and CholesterolBurdenon 
−treatment = (Cfollow−up ∗ Yearsfollow−up).
To estimate the average of TC and LDL-C, lipid pro-
files after baseline were collected every 3 months for the 
first 3 years, every 6 months for the period between 4 and 
10 years and once per year from year 11 until last follow-
up (these measurements were available only for patients 
on LA).






For descriptive statistics, continuous traits were pre-
sented as mean and standard deviation or as median and 
interquartile range as appropriate. Categorical traits were 
shown as number and proportion. Comparisons were 
carried out by Mann–Whitney for not-normally distrib-
uted and Student’s t-test for normally distributed vari-
ables. For differences between categorical traits, P-value 
was calculated by chi-square. Paired T test was used to 
evaluate the difference between untreated, lowest and 
last visit total and LDL-C as well as LDL-C burden pre- 
versus on-treatment.
Linear regression with stepwise method was used 
to evaluate the association between the variables and 
adjustments were performed for the following variables: 
genotype (Null/null mutation versus other), ethnic-
ity (European-non-Finnish vs. other), gender, untreated 
LDL-C and age at baseline. Not-normally distributed val-
ues were log-transformed before entering the model.
For the analysis on cardiovascular outcomes, we 
included only patients that had been exposed to lomi-
tapide or LA for more than 1  year [27]. The number of 
MACE was counted in each cohort and their incidence 
rates (IRs) were expressed as number of events per 1,000 
patient-year [25]. Cox proportional hazards model was 
TotalCholesterolBurden =
∑ Cholesterolburdenpre − treatment
Cholesterolburdenon− treatment
applied to investigate the predictors of incident MACE 
[25].
Statistical analyses were performed using the IBM Sta-
tistical Package for Social Sciences (IBM SPSS, version 
25.0, Inc. Chicago, IL). A P-value < 0.05 was considered 
statistically significant.
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